Why the study?
GPVI plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target for cardiovascular disease.
Design
Review
Key result
GPVI inhibitors, such as glenzocimab and revacept, represent a promising antithrombotic strategy for cardiovascular disease by targeting thrombosis without impairing haemostasis.
Authors
Loading...
Supports advancing GPVI inhibitors into randomized cardiovascular trials; leaves open their integration into clinical practice.
GPVI inhibition represents a promising antithrombotic strategy that targets thrombosis without impairing hemostasis, with several agents advancing in clinical trials.
Slater et al. (2024) conducted a review in Cardiovascular disease. GPVI inhibitors was evaluated. GPVI inhibitors, such as glenzocimab and revacept, represent a promising antithrombotic strategy for cardiovascular disease by targeting thrombosis without impairing haemostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: